INTRODUCTION
Haemophilia A is an X-linked bleeding disorder caused by a reduction in the coagulation protein FVIII (FVIII:C). The severity of bleeding is usually related to the level of FVIII:C. In the ISTH definition of haemophilia, patients with mild haemophilia A have FVIII:C levels of 5-40 IU/dl 1 and exhibit fewer bleeding episodes than those with the severe or moderate forms of the disease. In many patients, mild haemophilia A (MHA) is initially diagnosed by the finding of prolongation to the activated partial thromboplastin time (APTT) and reduction in FVIII:C level.
FVIII:C can be measured using the one-stage clotting assay (FVIII:C1), two-stage clotting assay (FVIII:C2) and the chromogenic (amidolytic) assay (FVIII:CR). The FVIII:C of most MHA patients is the same regardless of the assay method employed and these individuals are considered to be non-discrepant. However, approximately 30% of patients show marked differences in FVIII:C activity when assayed by the three methods and are regarded as assay discrepant [2] [3] [4] . The differences in levels may be two-fold or greater and for some patients, one or more of the FVIII:C assays may be in the normal range, potentially leading to an incorrect diagnosis.
It has recently become clear that two distinct types of assay discrepancy exist. 
Standard Coagulation Assays
Activated partial thromboplastin times and FVIII:C1 assays were performed with Actin FS APTT reagents and FVIII-deficient plasma (both Siemens, Marburg, Germany) according to standard methods 6 . FVIII:C2 assays were performed by an inhouse method using bovine factor V and platelet substitute (Diagnostic Reagents, Oxon, UK) 7 . FVIII:CR assays were performed with three commercial kits Siemens, Coamatic (Chromogenix, IL, Bedford, USA) and Technochrom (Pathway Diagnostics, Dorking, UK) using manufacturer's assay conditions.
Definition of assay discrepancy
Patients were denoted discrepant if a two-fold or greater difference in FVIII:C1 using Calibrated Automated Thrombogram (CAT) assays were performed with platelet poor plasma (PPP). Assay conditions, reproducibility and normal ranges were previously described 10 and were based on the method by Hemker et al 11 .
Genetic Analysis F8 mutation analysis was undertaken using either confirmation sensitive gel electrophoresis (CSGE) followed by DNA sequencing of amplicons displaying a migration shift 12 or by direct sequencing of the entire coding region and intron-exon boundaries of F8 13 . Nucleotide numbering of the F8 cDNA was from the A of the ATG initiation codon and protein from the initiator methionine at the start of FVIII using reference sequences for cDNA NM_000132.2 and protein NP_000123.1.
RESULTS

Incidence of assay discrepancy
84 individuals, with FVIII:C between 5 and 50 IU/dl by at least one method, were included in this study; 59 (70%) had less than a two-fold difference between FVIII:C1
and FVIII:C2 assays and were classified as non-discrepant. 10 patients (12%) had a FVIII:C1/FVIII:C2 ratio of ≥ 2.0 and were classified as "lower two-stage FVIII discrepancy"; 4 of these patients had a FVIII:C1 concentration in the normal range.
Fifteen patients (18%) had a FVIII:C1/FVIII:C2 ratio of ≤ 0.5 and were classified as the "lower one-stage FVIII discrepancy"; 13 of these patients had a FVIII:C2 concentration in the normal range. Figure 1 shows the patient distribution by FVIII level.
In non-discrepant patients the mean FVIII:C1/FVIII:C2 ratio was 1.0 (mean FVIII:C1 
DISCUSSION
Incidence of assay discrepancy
Assay discrepancy in patients with MHA was first highlighted in 1983 14 In 2002 a mutation, p.Tyr365Cys, was described which had the reverse effect; a reduced FVIII:C1 and higher FVIII:C2 and FVIII:CR levels 5 and no bleeding problems. The lower one-stage form has been associated with fewer mutations including p.Tyr365Cys (Tyr346Cys), p.Glu340Lys (Glu321Lys) and p.Glu739Lys
(Glu720Lys) 15 . In our centre in the UK, assay discrepancy linked to the p.Tyr365Cys mutation has a higher prevalence than lower two-stage discrepancy and this may reflect a possible common ancestor for the mutation 4 .
Assay discrepancy has not been uniformly defined in previous publications. We defined assay discrepancy as a two-fold or greater difference in FVIII:C1 (using Actin FS) and FVIII:C2 levels. 30% of patients in this study had a two-fold or greater difference in FVIII:C and were classified as assay discrepant, 12% of these had the lower two-stage form. This proportion is in agreement with other reports of the lower 4 carriers of p.Tyr365Cys were included in this study but only one exhibited discrepant FVIII:C levels so it is likely that ratio calculations for discrepancy will not work in all carriers of haemophilia due to the mix of normal and mutant FVIII. Standards Institute guidelines (H47-A2) 22 recommend that a suitable APTT reagent should be prolonged in plasmas which contain less than 30 IU/dl FVIII but the sensitivity of different reagents has been shown to vary significantly 23 [23] . A normal APTT was demonstrated in 11% of our patient cohort, distributed among the three groups; in each case the FVIII:C1 was above 30 IU/dl. This confirms that the APTT 13 cannot be relied upon as a screen for patients with MHA and the personal bleeding history of each patient is a much better indicator of haemostasis even when the APTT is normal. Thrombin generation was tested in eight of nine patients in this group.
APTT prolongation
Reduced ETP and peak thrombin was found in all except in two female carriers of p.Tyr365Cys, suggesting that thrombin generation assays are also a better indicator of haemostasis than the APTT.
Alternative reagents
In this study we categorised patients according to their FVIII:C by a single one-stage assay using Actin FS and our routine two-stage clotting assay, which is rarely performed in other centres. The two-stage clotting FVIII:C assay has been used in our haemophilia centre over several decades for the initial diagnosis of all haemophilia A cases whereas the one-stage clotting assay is the most commonly used FVIII:C assay elsewhere. This may confer a selection bias compared to other centres that use the one-stage assay alone. There are many APTT reagents used for the FVIII:C1 estimation worldwide, so our patients were also tested using another popular APTT reagent, Synthasil. Although a statistically significant difference was observed between the two reagents this was not clinically significant. The FVIII:CR assay is used in a small number of laboratories in place of FVIII:C2 and the three commercially available FVIII:CR assays used in the present study gave similar results to the FVIII:C2.
ROTEM
We have previously shown that thromboelastometry showed poor discrimination between normal individuals and those with MHA 9 but to the best of our knowledge no 14 studies have investigated the ability of ROTEM to detect FVIII:C assay discrepancy.
Some of the patients with MHA from our centre participated in both a previous 9 and the current study so it is not surprising that similar conclusions have been reached.
The only frequent abnormality in the non-discrepant group was the prolongation of the CT in both INTEM and low TF modified ROTEM and reduced MAXV and prolonged MAXVT in the low TF modified ROTEM. Overall however, more than half of all patients had normal parameters.
In this study, corn trypsin inhibitor was not added to the collection tube prior to blood collection to prevent initial contact activation at the low TF concentration. The ISTH working party for thromboelastography/thromboelastometry have suggested the use of CTI to improve sensitivity so the authors acknowledge that this may be a limitation of our study.
Although the number of patients with discrepancy studied was small, our observations indicate that in view of its poor sensitivity, it is unlikely that the ROTEM using the assay conditions described will be helpful in identifying patients with discrepant An ETP of 20-50% of normal has been reported in patients with haemophilia or rare coagulation deficiencies who demonstrate a severe bleeding tendency 25, 26 . There is also a relationship between bleeding and failure to normalise ETP in haemophilia patients with inhibitors treated with inhibitor bypass agents at the time of surgery 27 .
We therefore studied thrombin generation in patients with discrepant factor FVIII:C assays and compared these to patients with non-discrepant assays and normal subjects . This is similar to our results in the lower two-stage group. We showed the mean ETP to be 66% of normal in the lower two-stage group and 69% of normal in the non-discrepant group. Mean peak thrombin was 33% and 43% of normal respectively.
The relationship between lower one-stage discrepancy and thrombin generation has This confirms an advantage of thrombin generation over FVIII:C measurements.
Overall, the ETP and particularly the peak thrombin generation reflected FVIII:C2/CR measurements, including those patients who have a normal FVIII:C1 but reduced FVIII:C2 and those with normal APTT measurements. A statistical correlation was found between peak thrombin generation Actin FS FVIII:C1, Siemens FVIII:CR and Technochrom FVIII:CR but not with FVIII:C2 in contrast to our previous findings 9 . In our previous report we included several patients with severe and moderate haemophilia. Trossaërt reported a better correlation between FVIII:CR 17 less than 20 IU/dl and thrombin generation parameters 19 . This may be the reason for our currently contrasting findings when taken in conjunction with the relatively small number of patients in each group.
Conclusion
There remain many unresolved issues in the definition, diagnosis and management of patients with discrepant MHA. The definition of assay discrepancy has not been universally agreed which makes the linking of a particular mutation to assay discrepancy unpredictable. The overall incidence of discrepancy is thus unclear although it has been estimated at approximately 30% of patients. The genotype of a patient with MHA is not an accurate predictor of the degree of assay discrepancy but sometimes correlates to the bleeding diathesis, particularly in patients with the p.Tyr365Cys mutation where bleeding is rare.
The APTT, as a screening test, should not be relied upon to estimate FVIII:C activity because a normal result does not exclude the presence of a reduced FVIII:C, particularly in patients with assay discrepancy. At present, the FVIII:C2 assay is rarely performed so it is important to employ FVIII:CR assays that can detect patients with the lower two-stage but normal FVIII:C1 where the diagnosis of MHA will otherwise be missed.
Of the global assays, the standard or modified ROTEM (using our assay conditions) do not discriminate well between patients with MHA and normal subjects so their use in the diagnosis of assay discrepancy is not practicable. The ETP and peak thrombin generation using CAT however do show better discrimination between normal subjects and those with MHA. Overall, our results using CAT support the value of using a two-stage or chromogenic FVIII assay. Similar to other studies they also Table 2 . The genotype and number of subjects with each mutation found in the nondiscrepant, lower two-stage and lower one-stage groups. 5 patients had no record of mutation analysis and are denoted unknown. * indicates an amino acid change previously linked to assay discrepancy Table 3 . Rotational Thromboelastometry results shown for 27 non-discrepant, 5 lower two-stage discrepant and 9 lower one-stage discrepant patients using two reagents, commercially produced INTEM and an in-house low tissue factor modification. Median results are shown for each parameter with 1SD in brackets. Male ranges are quoted, the equivalent ranges for females, where different, are for INTEM: CFT 59-99s, α -angle 71-79°, MCF 53-65mm. and for low TF modification: CFT 104-209s, MCF 45-61s, AUC 4493-6061mmx60, MaxV 6-11s. The number of subjects who had results with abnormal ROTEM parameters is shown as a prolongation to CT, CFT, MaxVT and decrease in α -angle, MCF, AUC and MaxV. 
